Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QBX258
- Development stage
- Phase 1
- Lead developer
- Novartis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
QBX258 is an investigational intravenous dual-cytokine immunotherapy developed by Novartis. It combines the anti-interleukin-4 monoclonal antibody VAK694, also reported as VAK296, with the anti-interleukin-13 monoclonal antibody QAX576, also known as dectrekumab. By neutralizing IL-4 and IL-13, QBX258 suppresses type 2 helper T-cell inflammatory signaling implicated in asthma and fibrosis-associated breast cancer-related lymphedema. It was evaluated in Phase 2 asthma studies and in a small pilot study in breast cancer-related upper-extremity lymphedema. ([cancer.gov](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-il-4-il-13-combination-agent-qbx258))
- Brand names
- QBX258QBX-258QBX 258
- Other names
- anti-IL-4/IL-13 combination agentdectrekumab/VAK296VAK296 Plus QAX576VAK-296 Plus QAX576VAK 296 Plus QAX576VAK296/QAX576VAK694 plus QAX576VAK-694 plus QAX576VAK 694 plus QAX576VAK694/QAX576
02
Targets
IL-13 (Interleukin-13)IL-4 (Interleukin 4)
Beyond the preview
Go deeper on QBX258.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QBX258.